Martin Shkreli Exits Long Valeant Pharma (VRX)/short Allergan (AGN) Trade for Loss of 3%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Leerink PartnersRaises Price Target on Allergan (AGN) Following a MEDACorp Survey
October 28, 2015 7:05 AM EDTLeerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $342.00 (from $311.00), following a 60 person MEDACorp survey of US plastic surgeons and dermatologists. Specialists in the survey were bullish on Kybella and expect the drug to increase their submental fat patient... More
BTIG Thinks Valeant (VRX) Should Just Severe Ties with Philidor; PT Cut to $175
October 26, 2015 2:53 PM EDTBTIG is cutting its price target on Valeant Pharma (NYSE: VRX) from $210 down to $175, but maintaining a Buy rating following this morning's conference call.
Analyst Timothy Chiang commented, More details were provided this morning on Valeants call highlighting its relationship with Philidor,... More
